IPSC Earnings — Century Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
IPSC — Century Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.45
Market Cap$441.9M
P/E—
52W Range$0.43 – $3.04
Next Earnings2026-08-13
About Century Therapeutics, Inc. Common Stock
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
